Weight Loss$24.99–$30.99

Methylene Blue: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 12 sources cited

Overview

Methylene blue is a synthetic phenothiazine dye that has been repurposed as a mitochondrial enhancer and neuroprotective agent. Originally used as a medical dye and antimalarial, it functions as an alternative electron carrier in the mitochondrial electron transport chain, enhancing cellular energy production and reducing oxidative stress. It is one of the oldest synthetic drugs in medicine, with a history dating back to 1876.

Mechanism of Action

Methylene blue operates as a redox cycling agent that can accept electrons from NADH and transfer them directly to cytochrome c in the mitochondrial electron transport chain, effectively bypassing Complex I and Complex III — the primary sites of reactive oxygen species (ROS) generation. At low doses this makes it an electron cycler in the respiratory chain, with antioxidant and respiration-enhancing effects, and with cytochrome oxidase activity the step most clearly linked to its memory effects. This hormetic effect is concentration-dependent; at higher doses, methylene blue becomes a pro-oxidant. Its neuroprotective mechanism involves improved mitochondrial function in neurons, inhibition of tau protein aggregation, potent reversible inhibition of monoamine oxidase, and enhanced autophagic clearance of damaged organelles. Additionally, methylene blue inhibits nitric oxide synthase (NOS) and guanylate cyclase, which underlies its clinical use in treating methemoglobinemia and vasoplegic syndrome.

Methylene Blue Benefits: What the Research Shows

  • Rodriguez et al. (2017) in Brain Imaging and Behavior found a single low oral dose of methylene blue changed both task-related and resting-state brain networks in healthy adults
  • A 2016 study in Radiology showed a single low oral dose of methylene blue raised fMRI responses in the insula and in prefrontal, parietal and occipital cortex during attention and short-term memory tasks, with 7% more correct answers on memory retrieval in 26 healthy volunteers
  • Research in the Journal of Biological Chemistry (2015) showed methylthioninium salts inhibit tau aggregation in cell models and dissolve paired helical filaments taken from Alzheimer's brain tissue
  • Phase 3 trials of the methylene blue derivative LMTM in Alzheimer's disease missed their primary endpoints: in 891 patients neither dose beat control on cognition or daily function, and in the later LUCIDITY trial the treatment arms could not be separated at 52 weeks, with a cognitive difference appearing only in the mild cognitive impairment group at 78 and 104 weeks
  • Preclinical studies demonstrate neuroprotection against the mitochondrial toxin rotenone in rat striatum, with smaller lesions, preserved cytochrome oxidase activity and less oxidative stress
  • Randomised trials in people used a single 260 mg oral dose after extinction training: in claustrophobia it improved retention of extinction in those who had responded well but worsened it in those who had not, and in PTSD it added to evaluator-rated response without beating standard therapy

Methylene Blue Dosage

  • Cognitive enhancement: 0.5–2 mg/kg orally once daily (typically 15–60 mg for most adults)
  • Pharmaceutical grade (USP) is essential — industrial/chemical grade contains toxic contaminants
  • Start low at 0.5 mg/kg and titrate up over 1–2 weeks to assess tolerance
  • Best taken in the morning — may cause wakefulness if taken late
  • Take with food to reduce gastrointestinal discomfort
  • Cycle: 4–8 weeks on, 2–4 weeks off, though some protocols use continuous low-dose
  • Clinical methemoglobinemia dose: 1 mg/kg intravenously over 5 to 30 minutes per the ProvayBlue label (hospital setting only)
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Methylene Blue Side Effects & Safety

Known Side Effects

  • Blue-green discoloration of urine — universal and harmless, lasts 24–48 hours after dosing; stool may also have a blue-green tint
  • Blue staining of the mouth and tongue when taken orally — temporary and cosmetic
  • Gastrointestinal discomfort — nausea, diarrhea, or stomach pain, particularly at higher doses or without food
  • Serotonin syndrome risk — methylene blue is a potent reversible monoamine oxidase inhibitor and carries an FDA boxed warning against use with serotonergic drugs and opioids, including SSRIs, SNRIs, clomipramine, bupropion, buspirone, mirtazapine, linezolid and dextromethorphan
  • Headache — reported in some users, usually during the first week
  • Dose-dependent pro-oxidant effects — at doses above 4–5 mg/kg, the redox cycling shifts from antioxidant to pro-oxidant, potentially causing cellular damage

Safety Profile

Methylene blue has a well-characterized safety profile as an approved intravenous treatment for acquired methemoglobinemia, given at 1 mg/kg. Single oral doses of 260 mg have been given in controlled trials and were generally well tolerated. The most critical safety concern is its potent MAO-A inhibitory activity — combination with any serotonergic drug (SSRIs, SNRIs, triptans, tramadol, meperidine) creates a serious risk of serotonin syndrome, which can be fatal. The FDA label carries a boxed warning for serotonin syndrome with serotonergic drugs and opioids. The label contraindicates it in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency because of the risk of hemolytic anemia, and notes that hemolysis can occur during treatment even without that deficiency. Only pharmaceutical (USP) grade should be used — industrial or laboratory grade contains heavy metal contaminants. Chronic high-dose use has not been well-studied in healthy populations. Liver and kidney function should be normal before use.

What to Expect

Days 1–3: Urine turns blue-green (expected and harmless). Some GI adjustment may occur. Subtle increase in wakefulness and mental clarity reported by some users. Week 1: Improved focus and mental stamina become more noticeable. Energy levels may feel slightly elevated, particularly in the afternoon slump period. Weeks 2–4: Cognitive benefits plateau at their maximum. Users commonly report improved memory recall, sustained attention, and clearer thinking. Physical energy may also improve due to enhanced mitochondrial function. Weeks 4–8: Sustained benefits with continued use. After cessation, effects may persist for 1–2 weeks due to lasting mitochondrial improvements before gradually returning to baseline.

Common Stacks

Storage & Handling

Store methylene blue solution or powder at room temperature (15–25°C) in a tightly sealed container protected from light. Pharmaceutical-grade oral solutions are typically stable for 12–24 months unopened. Once opened, use within 6 months. Methylene blue is photosensitive and will degrade with prolonged light exposure. Do not mix with other solutions or compounds. Tablets/capsules should be stored in their original packaging away from moisture.

Pricing & Available Variants

$24.99 – $30.99price range
10mg/ML 50ml12mg x 60 Capsules

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. PROVAYBLUE (methylene blue) injection: prescribing information. American Regent, Inc., via DailyMed. 2024.
  2. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. 2016.
  3. Rodriguez P, Singh AP, Malloy KE, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav. 2017.
  4. Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry. 2014.
  5. Zoellner LA, Telch M, Foa EB, et al. Enhancing Extinction Learning in Posttraumatic Stress Disorder With Brief Daily Imaginal Exposure and Methylene Blue: A Randomized Controlled Trial. J Clin Psychiatry. 2017.
  6. Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016.
  7. Wischik CM, Stefanacci R, Bentham P, et al. Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. J Prev Alzheimers Dis. 2026.
  8. Harrington CR, Storey JM, Clunas S, et al. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. J Biol Chem. 2015.
  9. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012.
  10. Auchter AM, Barrett DW, Monfils MH, et al. Methylene Blue Preserves Cytochrome Oxidase Activity and Prevents Neurodegeneration and Memory Impairment in Rats With Chronic Cerebral Hypoperfusion. Front Cell Neurosci. 2020.
  11. Rojas JC, Simola N, Kermath BA, et al. Striatal neuroprotection with methylene blue. Neuroscience. 2009.
  12. Wu Y, Wang J, Wan X. Methylene Blue for Prevention of Perioperative Neurocognitive Disorders: Mechanisms and Recent Clinical Evidence. Drug Des Devel Ther. 2026.

Related Peptides

Track Methylene Blue in Your Protocol

Log your Methylene Blue doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free